Silver Book Fact

Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months in those without the mutation.

Lievre A, Bachet J, Boige V, Cayre A, et al. KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2008; 26(3): 374-9. http://www.ncbi.nlm.nih.gov/pubmed/18202412

Reference

Title
KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab
Publication
J Clin Oncol
Publication Date
2008
Authors
Lievre A, Bachet J, Boige V, Cayre A, et al.
Volume & Issue
Volume 26, Issue 3
Pages
374-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Cancer patients in the U.S. experience greater survival gains than those in European countries, and the value of additional gains exceeds the additional cost of care in the U.S.  
  • “Knowing that his disease had a high cure rate, Ben Dacus felt a sense of security at a time of great uncertainty. In 1988 he was diagnosed with Hodgkin’s disease. Strangely…  
  • Breast cancer incidence rates in women decreased 3.5% per year from 2001-2004, the first decrease observed in 20 years.  
  • 750 cancer-fighting medicines are currently in development.  
  • The Impact of Personalized Medicine on Cancer Survival in Years